– USA, MA – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company today announced the election of Dr. Tony Adamis (M.D.) to its Board of Directors.
Dr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry.
“It is my pleasure to welcome Dr. Adamis to EyePoint’s Board of Directors. Tony’s scientific and operational experience developing innovative ocular therapies from early discovery to commercial stages uniquely position him to provide valuable input as we work towards EyePoint’s goal of becoming the leader in ocular drug delivery technology. On behalf of the Board of Directors, we are excited to have Tony’s expertise and look forward to collaborating with him,” said Board Chair, Dr. Göran Ando.
Nancy Lurker, CEO added, “Dr. Adamis is a pioneer in the discovery and early development of anti-VEGF drugs for the treatment of ophthalmic diseases and will be an invaluable member of our Board of Directors. Tony brings a stellar track record of guiding the development of 20 medicines and 25 approvals by the U.S. Food and Drug Administration, and we look forward to leveraging his expertise as we continue to build our company and progress our lead pipeline asset, EYP-1901, through the clinic for multiple ophthalmic indications.”
About Dr. Anthony Adamis
Dr. Tony Adamis is best-known for his co-discovery of the role of vascular endothelial growth factors in ocular disease, including wet age-related macular degeneration and diabetic retinopathy. Before joining the EyePoint Board of Directors, Dr. Adamis served in various roles at Genentech/Roche, most recently as SVP, Development Innovation, and spearheaded the first FDA-approved drugs for diabetic macular edema and diabetic retinopathy, among several others. Previously, he was a co-founder, director, president, and CEO of Jerini Ophthalmic. Dr. Adamis also co-founded EyeTech Pharmaceuticals, which obtained FDA approval for the first anti-VEGF drug in ophthalmology, and was acquired by OSI Pharmaceuticals in 2005. Currently, Dr. Adamis is a lecturer in the Department of Ophthalmology at Harvard Medical School. Dr. Adamis holds an M.D. with Honors from the University of Chicago, Pritzker School of Medicine, and completed his ophthalmology residency at the University of Michigan and fellowship training at Harvard Medical School. He holds a B.S. in Biology from the University of Illinois, Urbana-Champaign.
“I am delighted to be joining EyePoint at this important time, as the Company is poised to expand its clinical trials for EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, for the potential treatment of multiple ophthalmic indications including wet AMD,” said Dr. Tony Adamis. “I look forward to supporting the Company’s mission of improving the lives of patients with serious eye disorders and bringing innovative products to patients in the United States and around the world.”
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA-approved products, including YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
For more information: https://eyepointpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
